Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
Semin Respir Crit Care Med. 2013 Dec;34(6):845-54. doi: 10.1055/s-0033-1358554. Epub 2013 Nov 20.
Stereotactic ablative radiotherapy (SABR), otherwise known as stereotactic body radiation therapy (SBRT), is an external beam treatment modality that offers the ability to deliver with high precision large doses of radiation over a limited number of fractions. SABR is currently a standard of care in the treatment of early-stage primary non-small cell lung cancers (NSCLCs) that are medically inoperable and for metastases in many anatomical locations. To date, local control and toxicity parameters with SABR for early-stage NSCLCs are comparable to those found in reports of experiences with surgical resection. It is increasingly apparent that some patients with borderline resectable lung primaries are also looking to SABR as a noninvasive means of therapy. However, randomized comparisons have not been completed to assess survival in operable patients. This review summarizes the advanced technology and radiation concepts that have helped clinicians optimize the use of stereotactic ablative therapies for lung cancer, with an emphasis on the rationale for future continued use of this advanced treatment modality.
立体定向消融放疗（SABR），也称为立体定向体部放疗（SBRT），是一种外照射治疗方式，能够以高精度在有限次数的分割中给予大剂量的辐射。SABR 目前是无法手术的早期原发性非小细胞肺癌（NSCLCs）和许多解剖部位转移瘤的标准治疗方法。迄今为止，SABR 治疗早期 NSCLC 的局部控制和毒性参数与手术切除报告中的结果相当。越来越明显的是，一些边界可切除的肺原发肿瘤患者也希望 SABR 成为一种非侵入性的治疗方法。然而，尚未完成随机比较来评估可手术患者的生存率。这篇综述总结了有助于临床医生优化立体定向消融治疗肺癌的先进技术和放射学概念，重点介绍了未来继续使用这种先进治疗方式的基本原理。
